ROCKVILLE, Md., Sept. 3, 2013 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE-MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that Jeffrey Riley, CEO, will present at the 15th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. Mr. Riley is scheduled to present at 12:05 p.m. (Eastern Time) on Monday, September 9, 2013 at the Millennium Broadway Hotel in New York City.
A live webcast of Synthetic Biologics’ presentation can be accessed by logging onto the internet at http://wsw.com/webcast/rrshq23/SYN. After the presentation, a replay will be archived and accessible for 30 days at the same website.
Mr. Riley, as well as Synthetic Biologics’ CFO, C. Evan Ballantyne, will be available to participate in one-on-one meetings with attendees who are registered for the conference. If you are an institutional investor, and would like to attend the Company’s presentation, please register for the Rodman & Renshaw conference using the following link www.rodm.com. Once your registration is confirmed, you will be prompted to log into the conference website and may request a one-on-one meeting with the Company.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE-MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics’ website at www.therivabio.com.
To download Synthetic Biologics’ investor relations mobile device app, which allows users access to the Company’s SEC documents, press releases and events, please click on the following links to download the IRapp on your iPhone and iPad or your Android mobile device.
SOURCE Synthetic Biologics, Inc.
Released September 3, 2013